A method to study the effect of bronchodilators on smoke retention in COPD patients: Study protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  van Dijk, WD ^a   Scheepers, PTJ ^a   Cremers, R ^a   Lenders, JWM ^a,b   Klerx, W ^c   van Weel, C ^a   Schermer, TRJ ^a   Heijdra, Y ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Voedsel en Waren Autoriteit Netherlands   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE; NICOTINE; SALBUTAMOL; TAR; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

ARTICLE; BRONCHODILATATION; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKE RETENTION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING; BREATH ANALYSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPOSURE; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG FUNCTION TEST; METHODOLOGY; NETHERLANDS; PATHOPHYSIOLOGY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR;

ADMINISTRATION, INHALATION; BREATH TESTS; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; INHALATION EXPOSURE; LUNG; NETHERLANDS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 79751526899     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-37     Document Type: Article

References (25)

1. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:549-555. 10.1513/pats.200709-148ET, 2645334, 18453370.
2. Curkendall SM, Lanes S, de Luise C, Stang MR, She D, Goehring E. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 2006, 21:803-813. 10.1007/s10654-006-9066-1, 17106760.
3. GOLD executive committee, GOLD science committee GOLD Guidelines 2009. 2010, GOLD executive committee, GOLD science committee., http://www.goldcopd.com
4. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004, 328:1519. 10.1136/bmj.38142.554479.AE, 437139, 15213107.
5. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Jiang L, Zhang X, Yusuf S, . Interheart Study Investigators Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006, 368:647-658. 10.1016/S0140-6736(06)69249-0, 16920470, Interheart Study Investigators.
6. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987, 317:1303-1309. 10.1056/NEJM198711193172102, 3683458.
7. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994, 272:1497-1505. 10.1001/jama.272.19.1497, 7966841.
8. Kuller LH, Ockene JK, Meilahn E, Wentworth DN, Svendsen KH, Neaton JD. Cigarette smoking and mortality. MRFIT Research Group. Prev Med 1991, 20:638-654. 10.1016/0091-7435(91)90060-H, 1758843.
9. Schermer T, Heijdra Y, Zadel S, van den Bemt L, Boonman-de Winter L, Dekhuijzen R, Smeele I. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med 2007, 101:1355-1362. 10.1016/j.rmed.2006.09.024, 17098407.
10. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, . Interheart Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952. 10.1016/S0140-6736(04)17018-9, 15364185, Interheart Study Investigators.
11. van Dijk WD, Heijdra Y, Scheepers PT, Lenders JW, van Weel C, Schermer TR. Interaction in COPD experiment (ICE): A hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease. Med Hypotheses 2010, 74:277-280. 10.1016/j.mehy.2009.09.012, 19800175.
12. Armitage AK, Dixon M, Frost BE, Mariner DC, Sinclair NM. The Effect of Inhalation Volume and Breath-Hold Duration on the Retention of Nicotine and Solanesol in the Human Respiratory Tract and on Subsequent Plasma Nicotine Concentrations During Cigarette Smoking. Contributions to Tobacco Research 2004, 21:240-249.
13. Feng S, Plunkett SE, Lam K, Kapur S, Muhammad R, Jin Y, Zimmermann M, Mendes P, Kinser R, Roethig HJ. A new method for estimating the retention of selected smoke constituents in the respiratory tract of smokers during cigarette smoking. Inhal Toxicol 2007, 19:169-179. 10.1080/08958370601052022, 17169864.
14. Invernizzi G, Boffi R, Ruprecht A, Barnes PJ, Kharitonov SA, Paredi P. Real-time measurement of particulate matter deposition in the lung. Biomarkers 2006, 11:221-232. 10.1080/13547500600648523, 16760131.
15. Shepperd CJ, St Charles FK, Lien M, Dixon M. Validation of Methods for Determining Consumer Smoked Cigarette Yields from Cigarette Filter Analysis. Contributions to Tobacco Research 2006, 22:176-184.
16. Brashier B, Dhembare P, Jantikar A, Mahadik P, Gokhale P, Gogtay JA, Salvi SS. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD. Respir Med 2007, 101:2464-2471. 10.1016/j.rmed.2007.07.006, 17719763.
17. Farmakotherapeutisch Kompas 2008/2009 2008, Amstelveen: college voor zorgverzekeringen.
18. CORESTA Routine Analytical Chemistry Sub-Group Coresta monitor test piece production and evaluation requirements. 2009, Accessed January 2010, CORESTA Routine Analytical Chemistry Sub-Group., http://www.coresta.org/Guides/Guide-No8-Monitor-Production_Apr09.pdf
19. Greenspan L. Humidity fixed points of binary saturated aqueous solutions. J of Research, National Bureau of Standards 1977, 81:89-96.
20. Chan YH. Randomised controlled trials (RCTs)--sample size: the magic number?. Singapore Med J 2003, 44:172-174.
21. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004, 43:1731-1737. 10.1016/j.jacc.2003.12.047, 15145091.
22. Bisoendial RJ, Kastelein JJ, Stroes ES. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 2007, 195:e10-e18. 10.1016/j.atherosclerosis.2007.04.053, 17669411.
23. Lee KW, Hill JS, Walley KR, Frohlich JJ. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. CMAJ 2006, 174:461-466. 10.1503/cmaj.050880, 1373750, 16477056.
24. Hoogendoorn M, Feenstra TL, Schermer TRJ, Hesselink AE, Rutten-van Molken MPH. Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Resp Med 2006, 100:83-86.
25. Borsboom GJ, van Pelt W, van Houwelingen HC, van Vianen BG, Schouten JP, Quanjer PH. Diurnal variation in lung function in subgroups from two Dutch populations: consequences for longitudinal analysis. Am J Respir Crit Care Med 1999, 159:1163-1171.